Section 5 of 6

Economic information and modeling report

3 evidence topics · 2 sources

Modeling overview

Summary

The modeling evidence in this report includes a DMD natural-history model of disease progression under standard of care and three Markov cohort state-transition frameworks evaluating a hypothetical intervention against standard of care in the United Kingdom. These are disease-level modeling resources, not economic evaluations of deramiocel. They do not establish a deramiocel-specific budget-impact estimate.

DMD natural-history model

“The natural history model provides data to inform disease progression under standard of care for economic evaluations of new therapies in Duchenne muscular dystrophy.” (opens the source at this quote in a new tab)

Disease-level economic-model frameworks

“three Markov cohort state-transition models” (opens the source at this quote in a new tab)
“a hypothetical intervention for DMD versus standard of care in a UK setting.” (opens the source at this quote in a new tab)

Deramiocel-specific cost-effectiveness or budget-impact results

No evidence found.

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.